Edition:
United Kingdom

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

0.71USD
20 Apr 2018
Change (% chg)

$-0.05 (-6.47%)
Prev Close
$0.76
Open
$0.73
Day's High
$0.73
Day's Low
$0.69
Volume
79,985
Avg. Vol
46,693
52-wk High
$8.10
52-wk Low
$0.69

Chart for

About

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies,... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $35.38
Shares Outstanding(Mil.): 15.59
Dividend: 29.10
Yield (%): --

Financials

  ALT.OQ Industry Sector
P/E (TTM): 0.08 84.02 32.74
EPS (TTM): 27.25 -- --
ROI: 326.16 1.58 14.38
ROE: 357.56 2.41 16.07

BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine

* ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION

27 Mar 2018

BRIEF-Altimmune Announces Pre-Clinical Data From Its Sparvax-L Anthrax Vaccine Program

* ALTIMMUNE ANNOUNCES PRE-CLINICAL DATA FROM ITS SPARVAX-L ANTHRAX VACCINE PROGRAM

12 Mar 2018

BRIEF-Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune

* HUDSON BAY CAPITAL MANAGEMENT LP‍ REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC​ AS OF DECEMBER 31, 2017 - SEC FILING Source text for Eikon: [http://bit.ly/2nwUAiB] Further company coverage:

02 Feb 2018

BRIEF-Altimmune Announces Allowance On Patent Covering Use Of Nasoshield In U.S.

* ALTIMMUNE ANNOUNCES NOTICE OF ALLOWANCE ON PATENT COVERING USE OF NASOSHIELD IN THE U.S. Source text for Eikon: Further company coverage:

23 Jan 2018

BRIEF-Altimmune Elects Mitchel Sayare As Chairman Of Its Board

* ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS

03 Jan 2018

BRIEF-Altimmune reports Q3 loss per share $2.05

* Altimmune announces third quarter 2017 financial results and provides corporate update

09 Nov 2017

Competitors

  Price Chg
Green Cross Corp (006280.KS) ₩217,000.00 +8,000.00
Pfizer Inc. (PFE.N) $36.63 +0.10
Panacea Biotec Limited (PNCA.NS) Rs293.10 +1.35
Bavarian Nordic A/S (BAVA.CO) kr.169.70 -5.70
Emergent Biosolutions Inc (EBS.N) $54.25 -0.12
Ibio Inc (IBIO.A) $0.16 -0.01
Soligenix Inc (SNGX.OQ) $1.71 -0.09
Pfenex Inc (PFNX.A) $5.45 +0.03

Earnings vs. Estimates